^
Association details:
| Biomarker: | EGFR exon 19 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer (EMERGING)
Excerpt:
To evaluate objective response rate (ORR) of Erlotinib versus combination of Gemcitabine plus Cisplatin as neoadjuvant treatment for stage IIIA- N2 NSCLC with EGFR activating mutation in exon 19 or 21.
Trial ID:
Source:
Title:
Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study
Published date:
12/10/2021
Excerpt:
...complex mutations in 24% of the patients with NSCLC who were evaluated for the study....Exon 19 or exon 21 mutations were present in 22 patients in the complex mutation group, and PFS time of these patients was 17.4 months (95% CI 6.6-28.2) and OS was 24.3 months (95% CI 0.0-89.4)….Overall response rate of the patients was similar in the erlotinib and afatinib arms (53.3% vs 52%, p= 0.218) (Table 3).
DOI:
10.21203/rs.3.rs-1125056/v1
Source:
Title:
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.
Published date:
05/19/2021
Excerpt:
This was a multicenter (17 centers in China) phase II randomized controlled trial of erlotinib (E) versus gemcitabine plus cisplatin (GC) as neoadjuvant/adjuvant therapy in pts with stage IIIA-N2 NSCLC with EGFR mutations in exon 19 or 21....The mOS was 42.2m in E and 36.9m in GC (HR 0.83, 95%CI 0.47-1.47, p = 0.513). The 3-,5-year OS rate were 58.6%, 40.8% in E and 55.9%, 27.6% in GC respectively (p3-y = 0.819, p5-y = 0.252)….Erlotinib as neoadjuvant/adjuvant therapy for resected N2 NSCLC was feasibility and had a promising OS.
DOI:
J Clin Oncol 39, 2021 (suppl 15; abstr 8502)
Trial ID:
Source:
Title:
Curative treatment in EGFR mt+ NSCLC stage III by induction TKI-chemotherapy combination: Feasibility and outcome in 7 cases
Published date:
09/14/2020
Excerpt:
7/7 patients had adenocarcinoma, 5 with EGFR exon 19 and 2 with EGFR L858R. Patients received erlotinib (n=2) or gefitinib (n=5) for 10 days followed by TKI in combination with chemotherapy (docetaxel/cisplatin (n=4), paclitaxel/carboplatin (n=3)) for 3 cycles. Median OS of the 7 patients was 51 months and median PFS was 17 months. In conclusion 1st generation TKI-chemotherapy induction in EGFR mt+ NSCLC is feasible...
Secondary therapy:
carboplatin + paclitaxel; cisplatin + docetaxel
Source:
Title:
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Excerpt:
This was a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib versus gemcitabine plus cisplatin (GC chemotherapy) as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 non-small-cell lung cancer with EGFR mutations in exon 19 or 21....Median PFS was significantly longer with erlotinib (21.5 months) versus GC chemotherapy (11.4 months; hazard ratio, 0.39; 95% CI, 0.23 to 0.67; P < .001). Observed adverse events reflected those most commonly seen with the two treatments.
DOI:
10.1200/JCO.19.00075
Trial ID:
